The information provided in this section is intended expressly for healthcare professionals in the United States. Click “OK” to enter if you are a US healthcare professional.
IMPORTANT SAFETY INFORMATION
WARNING: HEPATOTOXICITY - Severe and sometimes fatal hepatotoxicity has occurred in clinical trials. Monitor hepatic function prior to and during treatment. Interrupt and then reduce or discontinue STIVARGA for hepatotoxicity as manifested by elevated liver function tests or hepatocellular necrosis, depending upon severity and persistence. Continue reading below.